Lung Cancer: Introduction FeedbackA general introduction to Lung Cancer.Source: NHS Choices, 02 Aug 2013
Lung cancer is one of the most common and serious types of cancer. Over 41,000 people are diagnosed with the condition every year in the UK.
There are usually no signs or symptoms in the early stages of lung cancer, but many people with the condition will eventually develop symptoms including:
- a persistent cough
- coughing up blood
- persistent breathlessness
- unexplained tiredness and weight loss
- an ache or pain when breathing or coughing
You should see your GP if you have these symptoms.
Read more about the symptoms of lung cancer.
Types of lung cancer
Cancer that begins in the lungs is called primary lung cancer. Cancer that begins in another part of the body and spreads to the lungs is known as secondary lung cancer. This page is about primary lung cancer.
There are two main types of primary lung cancer. These are classified by the type of cells in which the cancer starts. They are:
- non-small-cell lung cancer – the most common type, accounting for more than 80% of cases; can be either squamous cell carcinoma, adenocarcinoma or large-cell carcinoma
- small-cell lung cancer – a less common type that usually spreads faster than non-small-cell lung cancer
The type of lung cancer you have will determine which treatments are recommended.
Read more about diagnosing lung cancer.
Who is affected
Lung cancer mainly affects older people. It is rare in people younger than 40, but the rates of lung cancer rise sharply with age. Lung cancer is most commonly diagnosed in people aged 70-74 years.
Although people who have never smoked can develop lung cancer, smoking is the main cause (about 90% of cases). This is because smoking involves regularly inhaling a number of different toxic substances.
Treating lung cancer
The treatment for lung cancer depends on the type of cancer, how far it has spread and how good your general health is.
If the condition is diagnosed early and the cancerous cells are confined to a small area, surgery to remove the affected area of lung is usually recommended.
If surgery is unsuitable due to your general health, radiotherapy to destroy the cancerous cells may be recommended instead.
If the cancer has spread too far for surgery or radiotherapy to be effective, chemotherapy is usually used.
Read more about the treating lung cancer.
As lung cancer does not usually cause noticeable symptoms until it has spread through much of the lungs or into other parts of the body, the outlook for the condition is not as good as many other types of cancer.
Overall, about 1 in 3 people with the condition will live for at least a year after they are diagnosed and fewer than 1 in 10 people will live at least five years.
However, survival rates can vary widely depending on how far the cancer has spread at the time of the diagnosis. Early diagnosis can make a big difference.
Read about living with lung cancer.
Lung Cancer: Guidance FeedbackThe most relevant search results for Lung Cancer from producers of guidance information.
- National Institute for Health and Care Excellence, 27 April 2011
- National Institute for Health and Care Excellence, 19 November 2012
British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults [PDF]British Thoracic Society, 01 August 2013
- Lung cancer
- Royal College of Radiologists, 01 January 2008
- Department of Health Western Australia - Diagnostic Imaging Pathways, 23 February 2012
- Department of Health Western Australia - Diagnostic Imaging Pathways, 23 February 2012
Lung Cancer: Commissioning FeedbackThe most relevant search results for Lung Cancer from producers of commissioning advice.
Information for the public
Lung Cancer: Information for the public FeedbackThe most relevant search results for Lung Cancer, from Department of Health accredited producers of patient information.
- CancerHelp UK, 11 November 2013
- Bupa , 04 November 2013
- CancerHelp UK, 25 October 2013
- CancerHelp UK, 06 November 2013
- NHS Choices, 02 August 2013
- CancerHelp UK, 09 May 2013
- CancerHelp UK, 14 February 2013
- CancerHelp UK, 28 January 2013
- CancerHelp UK, 19 December 2012
- CancerHelp UK, 19 December 2012
Lung Cancer: Ongoing Research FeedbackThe most relevant search results for Lung Cancer, from research trials.
Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy VolunteersUK Clinical Trials Gateway, 09 May 2009
Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung TestUK Clinical Trials Gateway, 15 August 2013
- UK Clinical Trials Gateway, 31 July 2012
- UK Clinical Trials Gateway, 26 March 2013
A CR-UK phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapyUK Clinical Trials Gateway, 29 January 2013
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung CancerUK Clinical Trials Gateway, 03 October 2012
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung CancerUK Clinical Trials Gateway, 04 April 2011
Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung CancerUK Clinical Trials Gateway, 17 July 2007
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF MutationsUK Clinical Trials Gateway, 07 April 2011
- UK Clinical Trials Gateway, 01 October 2010
Lung Cancer: Evidence Uncertainty FeedbackThe most relevant search results for Lung Cancer, highlighting areas where further research is needed.
The role of fine needle aspiration biopsy (FNAB) and core needle biopsy (CNB) - alone or in combination - for diagnosing lung cancer in patients with a lung lesionUK Database of Uncertainties about the Effects of Treatments, 11 September 2012
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseUK Database of Uncertainties about the Effects of Treatments, 04 June 2008
Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 16 September 2013
- UK Database of Uncertainties about the Effects of Treatments, 24 December 2012
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 20 July 2012
The biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 11 September 2012
Exercise training undertaken within 12 months following lung resection for patients with non-small cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 20 July 2012
Interobserver variation in the delineation of target volumes using positron emission tomography for non-small cell lung cancer patients with atelectasisUK Database of Uncertainties about the Effects of Treatments, 11 September 2012
- UK Database of Uncertainties about the Effects of Treatments, 01 December 2009
- UK Database of Uncertainties about the Effects of Treatments, 24 September 2009
Lung Cancer: Medicines FeedbackAppropriate medicines information for Lung Cancer supplied by Datapharm, a leading source of trusted, credible information about medicines.
Lung cancer - Medicines Information
- Bevacizumab (a generic version of Avastin)
- Bleo-Kyowa (a brand of Bleomycin Sulphate)
- Bleomycin sulphate
- Cyclophosphamide monohydrate
- Doxorubicin hydrochloride
- Doxorubin (a brand of Doxorubicin Hydrochloride)
- Endoxana (a brand of Cyclophosphamide Monohydrate)
- Epirubicin hydrochloride
- Eposin (a brand of Etoposide)
- Erlotinib hydrochloride (a generic version of Tarceva)
- Etoposide phosphate (a generic version of Etopophos)
- Gefitinib (a generic version of Iressa)
- Gemcitabine hydrochloride (a generic version of Gemzar)
- Maxtrex (a brand of Methotrexate)
- Mitomycin-C Kyowa (a brand of Mitomycin)
- Pemetrexed disodium (a generic version of Alimta)
- Pharmorubicin (a brand of Epirubicin Hydrochloride)
- Taxol (a brand of Paclitaxel)
- Taxotere (a brand of Docetaxel)
- Topotecan hydrochloride (a generic version of Hycamtin)
- Vincristine sulphate
- Vinorelbine tartrate
- Results are currently sorted by relevance (Sort results by: date)
- Results 1 - 10 (of 554)
...effective in preventing lung cancer. Chemoprevention...feasible for certain cancers and has been proposed...prevention of initial cancers and of second primary...previously treated for lung cancer and the possibility...agents to prevent lung and other common cancers (ATBC 1994; Omenn...Given the continuing cancer burden, the relatively...
Cochrane Database of Systematic Reviews, 17 October 2012 - Publisher: John Wiley & Sons, Ltd
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
...with stage III non-small-cell lung cancer: the ECOG 3598 study. Author...unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined...Carcinoma, Non-Small-Cell Lung [*drug therapy; mortality; pathology...
Cochrane Central Register of Controlled Trials, John Wiley & Sons Ltd, 01 February 2012 - Publisher: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
...Give in Celebration Breast cancer awareness month Become...deliver research Research by cancer type Funding for researchers...progress Progress on different cancers Cancer drugs Radiotherapy A...causes Lung cancer About lung cancer The lungs Causes Screening ...
CancerHelp UK, 30 April 2013
...common cancer after lung cancer, in terms of both incidence...mortality rates, colorectal cancers, England3 Table...selenium and risk of cancer: a prospective follow-up of nine years. Cancer 1987;60:145-148...rates for colorectal, lung and prostate cancers all fell.39 • Calcium...
National Institute for Health and Care Excellence, 23 June 2004 - Publisher: NICE - Publication type: Full Guidance
...Wu 2003; Zhang 2007) Lung cancer Three observational studies...reported data on the risk of lung cancer: one cohort study (Li 2008...2005; Zhong 2001) Oral cancer One cohort study (Ide 2007) reported data on the risk of cancers of oral cancers (cancer of...
Cochrane Database of Systematic Reviews, 07 July 2009 - Publisher: John Wiley & Sons, Ltd
Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk
...between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clinical Lung Cancer 2012; 13(1): 44-51 Status This...seven or more tablets weekly) may protect against lung cancer. Lung cancer risk was not associated with...
Database of Abstracts of Reviews of Effects, 17 July 2012 - Publisher: Centre for Reviews and Dissemination - Publication type: Systematic reviews
...associated with cancer Cigarette smoking...tobacco use and cancers of many sites...established as a cause of cancers of the lung, oral cavity...demonstrated by the lung cancer death rates in the...decreased risk” for cancers of the mouth, esophagus...decreased risk” of lung cancer. Thus, even for...
National Cancer Institute, USA, 26 September 2013
...gastrointestinal cancers. The combination...randomised trial having lung cancer prevention as the...2004), prostate cancer (Lawson 2007), and lung cancer (Slatore 2007...Cardiovascular diseases and cancers of the lung and gastrointestinal...
Cochrane Database of Systematic Reviews, 16 July 2008 - Publisher: John Wiley & Sons, Ltd
...metastatic or locally advanced lung cancer who received chemotherapy. They...cell (Haas 2005) or small cell lung cancer (Altinbas 2004), or both (Agnelli...versus control: symptomatic VTE in lung cancer Outcome or subgroup title ...
Cochrane Database of Systematic Reviews, 15 February 2012 - Publisher: John Wiley & Sons, Ltd
Report on the Evidence Regarding Off-Label Indications for Targeted Therapies used in Cancer Treatment
...in light of ovarian cancer’s high mortality rate...rectal, non-small cell lung, and breast cancers, and glioma.. However...of epithelial ovarian cancer. The published case...rectal, nonsmall cell lung, and breast cancers, and glioma.. However...of epithelial ovarian cancer. The published case...
Agency for Health Research and Quality, 13 January 2011
Searches related to “Lung Cancer”
- Clear all filters
- Areas of interest
Types of information
Select one or more of the 'type of information' options below to narrow your search
- Care Pathways(5)
- Drug / Medicines Management(45)
- Drug Prescribing and Safety(13)
- Drug Regulatory and Marketing(5)
- Evidence Summaries(69)
- Grey Literature(1)
- Health Technology Assessments(8)
- Known Uncertainties(25)
- Medicines Current Awareness(2)
- Ongoing Trials(28)
- Patient Information(201)
- Policy and Service Development(2)
- Primary Research(4)
- Systematic Reviews(33)
Start typing a Source name to narrow your search, or select one or more from the A-Z list
- Agency for Health Research and Quality - AHRQ (3)
- British Committee for Standards in Haematology - BCSH(8)
- Bupa (6)
- CancerHelp UK (55)
- Clinical Knowledge Summaries - CKS (27)
- Cochrane Central Register of Controlled Trials(1)
- Cochrane Database of Systematic Reviews (32)
- Database of Abstracts of Reviews of Effects - DARE (1)
- electronic Medicines Compendium - eMC (17)
- European Centre for Disease Prevention and Control(1)
- European Medicines Agency - EMA(5)
- European Society for Medical Oncology - ESMO(2)
- Finnish Medical Society Duodecim(1)
- Healthcare Quality Improvement Partnership - HQIP (1)
- Healthtalkonline (16)
- Joint Royal Colleges Ambulance Liaison Committee - JRCALC (1)
- Macmillan Cancer Support(34)
- National Cancer Institute, USA(2)
- National Institute for Health and Care Excellence - NICE (31)
- National Prescribing Centre - NPC (12)
- NHS Choices(56)
- NHS Employers (2)
- NIHR Journals Library - Health Technology Assessment(5)
- Patient UK(104)
- Renal Association (1)
- Scottish Intercollegiate Guidelines Network - SIGN (3)
- UK Clinical Trials Gateway - UKCTG(1)
- UK Database of Uncertainties about the Effects of Treatments - UK DUETS (25)
Medicines and devices
Start typing a Medicine or device name to narrow your search, or select one or more from the A-Z list
- Alpha tocopherol(29)
- Amphotericin b(25)
- Ascorbic acid(22)
- Fish oil(54)
- Folic acid(98)
- Folinic acid(70)
- Influenza vaccine(68)
- Mycophenolate mofetil(53)
- Mycophenolic acid(23)
- Nitric oxide(27)
- Parathyroid hormone(30)
- Pneumococcal vaccine(46)
- Sodium chloride(108)
- Sodium valproate(28)
- Tranexamic acid(102)
- Zoledronic acid(71)